Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-17T04:10:19.389Z Has data issue: false hasContentIssue false

Bacterial coinfections with coronavirus disease 2019 (COVID-19)

Published online by Cambridge University Press:  10 November 2021

Glen Huang*
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of California – Los Angeles, Los Angeles, California
Daisuke Furukawa
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of California – Los Angeles, Los Angeles, California
Bryant D. Yang
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of California – Los Angeles, Los Angeles, California
Brian J. Kim
Affiliation:
Department of Pharmacy, Olive View - University of California Los Angeles Medical Center, Sylmar, California
Arthur C. Jeng
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of California – Los Angeles, Los Angeles, CaliforniaDivision of Infectious Diseases, Department of Medicine, Olive View - University of California Los Angeles Medical Center, Sylmar, California
*
Author for correspondence: Glen Huang, DO, 10833 Le Conte Ave, Room 37-121CHS, Los Angeles, CA, 90095. E-mail: huanglen@gmail.com

Abstract

Background:

The pandemic caused by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) has dramatically increased cheshospitalizations, and it is often difficult to determine whether there is a bacterial or fungal coinfection at time of presentation. In this study, we sought to determine the rates of coinfection and utilization of antibiotics in SARS-CoV-2 disease.

Methods:

Retrospective chart review of patients hospitalized with COVID-19 pneumonia from April 13, 2020, to July 14, 2020.

Results:

In total, 277 patients were hospitalized for COVID-19 pneumonia during this period. Patients that received antibiotics within 48 hours of presentation were more likely to be febrile (59.3% vs 41.2%; P = .01) and to have leukocytosis (23.9% vs 5.9%; P < .01) and were less likely to have a procalcitonin level <0.25 ng/mL (58.8% vs 74.5%; P = .04). In total, 45 patients had positive blood cultures collected during hospitalization, 16 of which were clinically significant. Of the clinically significant blood cultures, 5 were collected <48 hours of admission. Moreover, 18 sputum cultures were clinically significant, 2 of which were collected within 48 hours of admission.

Conclusion:

Bacterial and fungal coinfections in COVID-19 appear to be rare on presentation; thus, this factor may be a good target for enhanced antibiotic stewardship.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Fig. 1.Frequencies of positive blood cultures (top) and positive sputum cultures (bottom).

Figure 1

Table 1.Characteristics of Patients With COVID-19

Figure 2

Table 2.Utilization of Antibiotics Within and After 48 Hours of Hospitalization